Dr. Estelamari Rodriguez, thoracic oncologist at the University of Miami’s Sylvester Comprehensive Cancer Center, joins the show to break down the latest advances in non-mutation driven and small cell lung cancer presented at the World Conference on Lung Cancer (WCLC) and how they translate into everyday clinical practice. She discusses pivotal studies including the ALCHEMIST trial exploring adjuvant therapy in ALK-fusion–positive early-stage lung cancer, PACIFIC-2 assessing concurrent immuno...
All content for Healthcare Unfiltered is the property of Chadi Nabhan and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dr. Estelamari Rodriguez, thoracic oncologist at the University of Miami’s Sylvester Comprehensive Cancer Center, joins the show to break down the latest advances in non-mutation driven and small cell lung cancer presented at the World Conference on Lung Cancer (WCLC) and how they translate into everyday clinical practice. She discusses pivotal studies including the ALCHEMIST trial exploring adjuvant therapy in ALK-fusion–positive early-stage lung cancer, PACIFIC-2 assessing concurrent immuno...
Returning guest Dr. Amer Zeidan of Yale Medicine and Smilow Cancer Hospital joins to discuss how clinicians should approach low-risk Myelodysplastic Syndrome (MDS), which is most often managed in community settings. He breaks down how to risk-stratify patients using molecular and prognostic markers, when to treat versus observe, and his preferred first-line therapies in today’s landscape. Dr. Zeidan also delves into the COMMANDS trial and the role of luspatercept, emerging questions shaping t...
Healthcare Unfiltered
Dr. Estelamari Rodriguez, thoracic oncologist at the University of Miami’s Sylvester Comprehensive Cancer Center, joins the show to break down the latest advances in non-mutation driven and small cell lung cancer presented at the World Conference on Lung Cancer (WCLC) and how they translate into everyday clinical practice. She discusses pivotal studies including the ALCHEMIST trial exploring adjuvant therapy in ALK-fusion–positive early-stage lung cancer, PACIFIC-2 assessing concurrent immuno...
